Adachi S, Hirashiki A, Kondo T, Nakaguro M, Ogawa A, Miyaji K, Matsubara H, Yokoi
T and Murohara T (2014) Imatinib is partially effective for the treatment of pulmonary
capillary hemangiomatosis. Intern Med 53, 603-607.
Anazawa R, Terada J, Sakao S, Shigeta A, Tanabe N and Tatsumi K (2019) Features of
radiological and physiological findings in pulmonary capillary hemangiomatosis: an
updated pooled analysis of confirmed diagnostic cases. Pulm Circ 9,
2045894019896696.
Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk AC, Rosenzweig
EB, Bayrak-Toydemir P, Mao R, Cahill BC, et al (2014) EIF2AK4 mutations in
pulmonary capillary hemangiomatosis. Chest 145, 231-236.
Chaisson NF, Dodson MW and Elliott CG (2016) Pulmonary Capillary
Hemangiomatosis and Pulmonary Veno-occlusive Disease. Clin Chest Med 37, 523534.
D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman
AP, Goldring RM, Groves BM, Kernis JT and et al. (1991) Survival in patients with
primary pulmonary hypertension. Results from a national prospective registry. Ann
Intern Med 115, 343-349.
Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F,
Bonnet D, Dorfmuller P, et al (2014) EIF2AK4 mutations cause pulmonary venoocclusive disease, a recessive form of pulmonary hypertension. Nat Genet 46, 65-69.
Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M,
Matsubara H, Momomura SI, et al (2019) Guidelines for the Treatment of Pulmonary
Hypertension (JCS 2017/JPCPHS 2017). Circ J 83, 842-945.
Ghofrani HA, Seeger W and Grimminger F (2005) Imatinib for the treatment of
pulmonary arterial hypertension. N Engl J Med 353, 1412-1413.
40
Gupta S, Gupta A, Rehman S, Ocak I, Domsic RT, Schneider F and George MP (2019)
Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients
undergoing lung transplantation. ERJ Open Res 5.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA,
Grimminger F, Grunig E, Hassoun PM, et al (2013) Imatinib mesylate as add-on therapy
for pulmonary arterial hypertension: results of the randomized IMPRES study.
Circulation 127, 1128-1138.
Holcomb BW, Jr., Loyd JE, Ely EW, Johnson J and Robbins IM (2000) Pulmonary
veno-occlusive disease: a case series and new observations. Chest 118, 1671-1679.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J,
Coats AJS, Escribano-Subias P, Ferrari P, et al (2023) 2022 ESC/ERS Guidelines for the
diagnosis and treatment of pulmonary hypertension. Eur Respir J 61.
Kataoka M, Yanagisawa R, Fukuda K, Yoshino H and Satoh T (2012) Sorafenib is
effective in the treatment of pulmonary veno-occlusive disease. Cardiology 123, 172174.
Koiwa H, Tsujino I, Ikeda D, Ohira H, Tanino M and Nishimura M (2011) An autopsy
case of pulmonary veno-occlusive disease refractory to imatinib. Eur Respir J 37, 968970.
Luo Q, Jin Q, Zhao Z, Zhao Q, Yu X, Yan L, Zhang Y, Xiong C and Liu Z (2019)
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink? BMC Pulm
Med 19, 257.
Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C, Rabiller A,
Haque R, Sitbon O, Jais X, et al (2008) Pulmonary veno-occlusive disease: clinical,
functional, radiologic, and hemodynamic characteristics and outcome of 24 cases
confirmed by histology. Medicine (Baltimore) 87, 220-233.
41
Montani D, Girerd B, Jais X, Levy M, Amar D, Savale L, Dorfmuller P, Seferian A, Lau
EM, Eyries M, et al (2017) Clinical phenotypes and outcomes of heritable and sporadic
pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 5,
125-134.
Montani D, Jais X, Price LC, Achouh L, Degano B, Mercier O, Mussot S, Fadel E,
Dartevelle P, Sitbon O, et al (2009) Cautious epoprostenol therapy is a safe bridge to
lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 34, 1348-1356.
Montani D, Lau EM, Dorfmuller P, Girerd B, Jais X, Savale L, Perros F, Nossent E,
Garcia G, Parent F, et al (2016) Pulmonary veno-occlusive disease. Eur Respir J 47,
1518-1534.
Nayyar D, Muthiah K, Kumarasinghe G, Hettiarachchi R, Celermajer D, Kotlyar E and
Keogh A (2014) Imatinib for the treatment of pulmonary arterial hypertension and
pulmonary capillary hemangiomatosis. Pulm Circ 4, 342-345.
O'Keefe MC and Post MD (2015) Pulmonary capillary hemangiomatosis: a rare cause
of pulmonary hypertension. Arch Pathol Lab Med 139, 274-277.
Ogawa A, Ejiri K and Matsubara H (2014) Long-term patient survival with
idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan.
Life Sci 118, 414-419.
Ogawa A, Miyaji K and Matsubara H (2017) Efficacy and safety of long-term imatinib
therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary
hemangiomatosis. Respir Med 131, 215-219.
Ogawa A, Miyaji K, Yamadori I, Shinno Y, Miura A, Kusano KF, Ito H, Date H and
Matsubara H (2012) Safety and efficacy of epoprostenol therapy in pulmonary venoocclusive disease and pulmonary capillary hemangiomatosis. Circ J 76, 1729-1736.
Ogawa A, Sakao S, Tanabe N, Matsubara H and Tatsumi K (2019) Use of vasodilators
for the treatment of pulmonary veno-occlusive disease and pulmonary capillary
hemangiomatosis: A systematic review. Respir Investig 57, 183-190.
42
Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF and Vonk-Noordegraaf
A (2008) Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur
Respir J 32, 232-235.
Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF,
Dijkmans BA, Postmus PE, Mooi WJ, Heijdra Y and Grunberg K (2009) Pulmonary
arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy.
Eur Respir J 34, 371-379.
Ranchoux B, Gunther S, Quarck R, Chaumais MC, Dorfmuller P, Antigny F, Dumas SJ,
Raymond N, Lau E, Savale L, et al (2015) Chemotherapy-induced pulmonary
hypertension: role of alkylating agents. Am J Pathol 185, 356-371.
Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, Simonneau G and
Musset D (2004) Pulmonary hypertension: CT of the chest in pulmonary venoocclusive
disease. AJR Am J Roentgenol 183, 65-70.
Sato H, Sugimura K, Miura M, Konno R, Kozu K, Yaoita N, Shimizu T, Yamamoto S,
Aoki T, Tatebe S, et al (2019) Beneficial Effects of Imatinib in a Patient with Suspected
Pulmonary Veno-Occlusive Disease. Tohoku J Exp Med 247, 69-73.
Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A,
Abe K, Tsujino I, et al (2017) Effectiveness and Outcome of Pulmonary Arterial
Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial
Hypertension. Circ J 82, 275-282.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, MatucciCerinic M, Naden RP, Medsger TA, Jr., Carreira PE, et al (2013) 2013 classification
criteria for systemic sclerosis: an American college of rheumatology/European league
against rheumatism collaborative initiative. Ann Rheum Dis 72, 1747-1755.
Wada H, Nakajima T, Suzuki H, Anazawa R, Narita T, Terada J, Yoshida S, Tatsumi K,
Nakatani Y and Yoshino I (2019) Pulmonary capillary hemangiomatosis diagnosed by
pathology of explanted lungs: a unique etiology serves as a key of clinical diagnosis.
Gen Thorac Cardiovasc Surg 67, 332-335.
43
Zhang L, Wang Y and Zhang R (2021) Good response to pulmonary arterial
hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case
report. Medicine (Baltimore) 100, e27334.
44
...
論文の公開元へ
